載入中
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
前收盤價
US$3.63
−US$0.23 · -5.96%
盤中時間採用ET。市場資料可能有所延遲。
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
日內區間
目前US$3.63
52週區間
目前US$3.63
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
17
估值過高
情緒
42
多空交錯
風險
74
高風險
動能
33
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
日內區間
目前US$3.63
52週區間
目前US$3.63
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 490.4萬 USD | 517.4萬 USD | 452.9萬 USD | 550.8萬 USD | 447.4萬 USD |
| 銷貨成本 | 153.1萬 USD | 3442.6萬 USD | 97.2萬 USD | 3501.7萬 USD | 2001.5萬 USD |
| 毛利 | 337.3萬 USD | −2925.2萬 USD | 355.7萬 USD | −2950.9萬 USD | −1554.1萬 USD |
| 研究與開發 | 2371.7萬 USD | 3442.6萬 USD | 3377萬 USD | 3501.7萬 USD | 2001.5萬 USD |
| 銷售、一般及管理費用 | 1240.9萬 USD | 1318.4萬 USD | 1067.7萬 USD | 743.7萬 USD | 828.1萬 USD |
| 營業費用 | 3459.5萬 USD | 1318.4萬 USD | 4444.7萬 USD | 743.7萬 USD | 828.1萬 USD |
| 利息收入 | 38.8萬 USD | 69.7萬 USD | 17.9萬 USD | 2.9萬 USD | 5000 USD |
| 利息支出 | 1659萬 USD | 1074.2萬 USD | 262.6萬 USD | 2.9萬 USD | 6.4萬 USD |
| 折舊和攤銷 | 153.1萬 USD | 132.5萬 USD | 97.2萬 USD | 89.2萬 USD | 116.9萬 USD |
| 營業利益 | −3122.2萬 USD | −4243.6萬 USD | −4089萬 USD | −3694.6萬 USD | −2382.2萬 USD |
| 淨利 | −1.74億 USD | −1891.6萬 USD | −6904.5萬 USD | −3691.7萬 USD | −2315.5萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI192.63萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM77.75萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF69.36萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO42.82萬0.00%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO37.35萬0.00%180億 USD0.06%US$112.66+0.50%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM15萬0.13%1.17億 USD0.73%US$15.9402+0.25%
iShares Micro-Cap ETFIWC14.53萬0.01%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG7.09萬0.00%17億 USD0.06%US$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
